Skip to main content
Erschienen in: Current Diabetes Reports 4/2012

01.08.2012 | Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Glycemic Control in Diabetic Dialysis Patients and the Burnt-Out Diabetes Phenomenon

verfasst von: Jongha Park, Paungpaga Lertdumrongluk, Miklos Z. Molnar, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh

Erschienen in: Current Diabetes Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Diabetes mellitus (DM) is the most common cause of end-stage kidney disease and a major risk of morbidity and mortality. It is not clear whether medical management of DM has any significant beneficial effect on clinical outcomes at the end-stage of diabetic nephropathy with full-blown micro- and macro-angiopathic complications. Both loss of kidney function and dialysis treatment interfere with glucose homeostasis and confound glycemic control. Given the unique nature of uremic milieu and dialysis therapy related alterations, there have been some debates about reliance on the conventional measures of glycemic control, in particular the clinical relevance of hemoglobin A1c and its recommended target range of <7 % in diabetic dialysis patients. Moreover, a so-called burnt-out diabetes phenomenon has been described, in that many diabetic dialysis patients experience frequent hypoglycemic episodes prompting cessation of their anti-diabetic therapies transiently or even permanently. By reviewing the recent literature we argue that the use of A1c for management of diabetic dialysis patients should be encouraged if appropriate target ranges specific for these patients (e.g. 6 to 8 %) are used. We also argue that “burnt-out diabetes” is a true biologic phenomenon and highly prevalent in dialysis patients with established history and end-stage diabetic nephropathy and explore the role of protein-energy wasting to this end. Similarly, the J- or U-shaped associations between A1c or blood glucose concentrations and mortality are likely biologically plausible phenomena that should be taken into consideration in the management of diabetic dialysis patients to avoid hypoglycemia and its fatal consequences in diabetic dialysis patients.
Literatur
1.
Zurück zum Zitat Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis. 2008;52:766–77.PubMedCrossRef Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis. 2008;52:766–77.PubMedCrossRef
2.
Zurück zum Zitat Kovesdy CP, Kalantar-Zadeh K. Enter the dragon: a Chinese epidemic of chronic kidney disease? Lancet. 2012;379:783–5.PubMedCrossRef Kovesdy CP, Kalantar-Zadeh K. Enter the dragon: a Chinese epidemic of chronic kidney disease? Lancet. 2012;379:783–5.PubMedCrossRef
4.
Zurück zum Zitat Kalantar-Zadeh K, Derose SF, Nicholas S, et al. Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr. 2009;19:33–7.PubMedCrossRef Kalantar-Zadeh K, Derose SF, Nicholas S, et al. Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr. 2009;19:33–7.PubMedCrossRef
5.
Zurück zum Zitat Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010;23:148–56.PubMedCrossRef Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010;23:148–56.PubMedCrossRef
6.
Zurück zum Zitat Fluckiger R, Harmon W, Meier W, et al. Hemoglobin carbamylation in uremia. N Engl J Med. 1981;304:823–7.PubMedCrossRef Fluckiger R, Harmon W, Meier W, et al. Hemoglobin carbamylation in uremia. N Engl J Med. 1981;304:823–7.PubMedCrossRef
7.
Zurück zum Zitat Kalantar-Zadeh K, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial. 2004;17:445–65.CrossRef Kalantar-Zadeh K, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial. 2004;17:445–65.CrossRef
8.
Zurück zum Zitat De Marchi S, Cecchin E, Camurri C, et al. Origin of glycosylated hemoglobin A1 in chronic renal failure. Int J Artif Organs. 1983;6:77–82.PubMed De Marchi S, Cecchin E, Camurri C, et al. Origin of glycosylated hemoglobin A1 in chronic renal failure. Int J Artif Organs. 1983;6:77–82.PubMed
9.
Zurück zum Zitat Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12:749–53.PubMedCrossRef Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12:749–53.PubMedCrossRef
10.
Zurück zum Zitat Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32:1137–42.PubMedCrossRef Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32:1137–42.PubMedCrossRef
11.
Zurück zum Zitat Riveline JP, Hadjadj S. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes: response to Kazempour-Ardebili et al. Diabetes Care. 2009;32:e155–6. author reply.PubMedCrossRef Riveline JP, Hadjadj S. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes: response to Kazempour-Ardebili et al. Diabetes Care. 2009;32:e155–6. author reply.PubMedCrossRef
12.
Zurück zum Zitat Williams ME, Lacson Jr E, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503–9.PubMedCrossRef Williams ME, Lacson Jr E, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503–9.PubMedCrossRef
13.
Zurück zum Zitat Shurraw S, Majumdar SR, Thadhani R, et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis. 2010;55:875–84.PubMedCrossRef Shurraw S, Majumdar SR, Thadhani R, et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis. 2010;55:875–84.PubMedCrossRef
14.
Zurück zum Zitat Freedman BI, Andries L, Shihabi ZK, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol. 2011;6:1635–43.PubMedCrossRef Freedman BI, Andries L, Shihabi ZK, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol. 2011;6:1635–43.PubMedCrossRef
15.
Zurück zum Zitat Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062–8.PubMedCrossRef Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062–8.PubMedCrossRef
16.
Zurück zum Zitat Kumeda Y, Inaba M, Shoji S, et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf). 2008;69:556–61.CrossRef Kumeda Y, Inaba M, Shoji S, et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf). 2008;69:556–61.CrossRef
17.
Zurück zum Zitat Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896–903.PubMedCrossRef Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896–903.PubMedCrossRef
18.
19.
Zurück zum Zitat Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–11.PubMedCrossRef Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–11.PubMedCrossRef
20.
Zurück zum Zitat Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997;12:2105–10.PubMedCrossRef Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997;12:2105–10.PubMedCrossRef
21.
Zurück zum Zitat Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909–13.PubMedCrossRef Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909–13.PubMedCrossRef
22.
Zurück zum Zitat Mcmurray SD, Johnson G, Davis S, Mcdougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis. 2002;40:566–75.PubMedCrossRef Mcmurray SD, Johnson G, Davis S, Mcdougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis. 2002;40:566–75.PubMedCrossRef
23.
Zurück zum Zitat Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006;29:1496–500.PubMedCrossRef Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006;29:1496–500.PubMedCrossRef
24.
Zurück zum Zitat • Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–55. This is a large study in which A1c is associated with mortality after adjusting possible confounders including demographics, comorbidities, anemia and nutrition. It also shows a significant prevalence of A1c level <6 % in HD patients. PubMedCrossRef • Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–55. This is a large study in which A1c is associated with mortality after adjusting possible confounders including demographics, comorbidities, anemia and nutrition. It also shows a significant prevalence of A1c level <6 % in HD patients. PubMedCrossRef
25.
Zurück zum Zitat Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int. 2006;70:1392–4.PubMedCrossRef Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int. 2006;70:1392–4.PubMedCrossRef
26.
Zurück zum Zitat Williams ME, Lacson Jr E, Teng M, et al. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Am J Nephrol. 2009;29:54–61.PubMedCrossRef Williams ME, Lacson Jr E, Teng M, et al. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Am J Nephrol. 2009;29:54–61.PubMedCrossRef
27.
Zurück zum Zitat • Williams ME, Lacson Jr E, Wang W, et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent cox model analyses. Clin J Am Soc Nephrol. 2010;5:1595–601. The authors supplements their previous observation, in which A1c did not related to mortality in dialysis patients, by extending follow-up to 3 years and using time-dependent survival models. They show only extremes of glycemia are associated with inferior survival, suggesting an aggressive glycemic control is not mandatory in this population. PubMedCrossRef • Williams ME, Lacson Jr E, Wang W, et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent cox model analyses. Clin J Am Soc Nephrol. 2010;5:1595–601. The authors supplements their previous observation, in which A1c did not related to mortality in dialysis patients, by extending follow-up to 3 years and using time-dependent survival models. They show only extremes of glycemia are associated with inferior survival, suggesting an aggressive glycemic control is not mandatory in this population. PubMedCrossRef
28.
Zurück zum Zitat Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol. 2011;6:1041–8.PubMedCrossRef Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol. 2011;6:1041–8.PubMedCrossRef
29.
Zurück zum Zitat Molnar MZ, Huang E, Hoshino J, et al. Association of pretransplant glycemic control with posttransplant outcomes in diabetic kidney transplant recipients. Diabetes Care. 2011;34:2536–41.PubMedCrossRef Molnar MZ, Huang E, Hoshino J, et al. Association of pretransplant glycemic control with posttransplant outcomes in diabetic kidney transplant recipients. Diabetes Care. 2011;34:2536–41.PubMedCrossRef
30.
Zurück zum Zitat • Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61:708–15. This is a very recent, large, nationally representative study. It demonstrates a J-shaped association between A1c (or glucose) and mortality. Of noteworthy about 40 % of HD patients have A1c levels <6 % linking to inferior survival. PubMedCrossRef • Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61:708–15. This is a very recent, large, nationally representative study. It demonstrates a J-shaped association between A1c (or glucose) and mortality. Of noteworthy about 40 % of HD patients have A1c levels <6 % linking to inferior survival. PubMedCrossRef
31.
Zurück zum Zitat Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920–7.PubMedCrossRef Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920–7.PubMedCrossRef
32.
Zurück zum Zitat Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4–8.PubMedCrossRef Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4–8.PubMedCrossRef
33.
Zurück zum Zitat Dzurik R, Spustova V, Lajdova I. Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron. 1993;65:108–10.PubMedCrossRef Dzurik R, Spustova V, Lajdova I. Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron. 1993;65:108–10.PubMedCrossRef
34.
Zurück zum Zitat Mccaleb ML, Izzo MS, Lockwood DH. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest. 1985;75:391–6.PubMedCrossRef Mccaleb ML, Izzo MS, Lockwood DH. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest. 1985;75:391–6.PubMedCrossRef
35.
Zurück zum Zitat Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes. 1985;34:1152–9.PubMedCrossRef Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes. 1985;34:1152–9.PubMedCrossRef
36.
Zurück zum Zitat Friedman JE, Dohm GL, Elton CW, et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Physiol. 1991;261:E87–94.PubMed Friedman JE, Dohm GL, Elton CW, et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Physiol. 1991;261:E87–94.PubMed
37.
Zurück zum Zitat Akmal M, Massry SG, Goldstein DA, et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985;75:1037–44.PubMedCrossRef Akmal M, Massry SG, Goldstein DA, et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985;75:1037–44.PubMedCrossRef
38.
Zurück zum Zitat Mak RH, Bettinelli A, Turner C, et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60:229–33.PubMedCrossRef Mak RH, Bettinelli A, Turner C, et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60:229–33.PubMedCrossRef
39.
Zurück zum Zitat Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13–6.PubMedCrossRef Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13–6.PubMedCrossRef
40.
Zurück zum Zitat Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311–20.PubMedCrossRef Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311–20.PubMedCrossRef
41.
Zurück zum Zitat Lee SW, Dai G, Hu Z, et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol. 2004;15:1537–45.PubMedCrossRef Lee SW, Dai G, Hu Z, et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol. 2004;15:1537–45.PubMedCrossRef
42.
Zurück zum Zitat Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–8.PubMedCrossRef Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–8.PubMedCrossRef
43.
Zurück zum Zitat Cano N. Bench-to-bedside review: glucose production from the kidney. Crit Care. 2002;6:317–21.PubMedCrossRef Cano N. Bench-to-bedside review: glucose production from the kidney. Crit Care. 2002;6:317–21.PubMedCrossRef
44.
Zurück zum Zitat Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18:103–21.PubMed Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18:103–21.PubMed
45.
Zurück zum Zitat Heaton A, Taylor R, Johnston DG, et al. Hepatic and peripheral insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Clin Sci (Lond). 1989;77:383–8. Heaton A, Taylor R, Johnston DG, et al. Hepatic and peripheral insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Clin Sci (Lond). 1989;77:383–8.
46.
Zurück zum Zitat Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19:564–7.PubMedCrossRef Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19:564–7.PubMedCrossRef
47.
Zurück zum Zitat Mamoun AH, Anderstam B, Sodersten P, et al. Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Kidney Int. 1996;49:1276–82.PubMedCrossRef Mamoun AH, Anderstam B, Sodersten P, et al. Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Kidney Int. 1996;49:1276–82.PubMedCrossRef
48.
Zurück zum Zitat Walls EK, Koopmans HS. Differential effects of intravenous glucose, amino acids, and lipid on daily food intake in rats. Am J Physiol. 1992;262:R225–234.PubMed Walls EK, Koopmans HS. Differential effects of intravenous glucose, amino acids, and lipid on daily food intake in rats. Am J Physiol. 1992;262:R225–234.PubMed
49.
Zurück zum Zitat Von Baeyer H, Gahl GM, Riedinger H, et al. Adaptation of CAPD patients to the continuous peritoneal energy uptake. Kidney Int. 1983;23:29–34.CrossRef Von Baeyer H, Gahl GM, Riedinger H, et al. Adaptation of CAPD patients to the continuous peritoneal energy uptake. Kidney Int. 1983;23:29–34.CrossRef
50.
Zurück zum Zitat Sharma R, Rosner MH. Glucose in the dialysate: historical perspective and possible implications? Hemodial Int. 2008;12:221–6.PubMedCrossRef Sharma R, Rosner MH. Glucose in the dialysate: historical perspective and possible implications? Hemodial Int. 2008;12:221–6.PubMedCrossRef
51.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef
52.
Zurück zum Zitat Patel A, Macmahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef Patel A, Macmahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef
53.
Zurück zum Zitat Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287:2563–2569. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287:2563–2569.
54.
Zurück zum Zitat Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.PubMedCrossRef Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.PubMedCrossRef
55.
Zurück zum Zitat Kalantar-Zadeh K. A1c remains gold standard outcome predictor in diabetic dialysis patients. Diabetes Care, July 2012 doi:10.2337/dc12-0483. Kalantar-Zadeh K. A1c remains gold standard outcome predictor in diabetic dialysis patients. Diabetes Care, July 2012 doi:10.​2337/​dc12-0483.
Metadaten
Titel
Glycemic Control in Diabetic Dialysis Patients and the Burnt-Out Diabetes Phenomenon
verfasst von
Jongha Park
Paungpaga Lertdumrongluk
Miklos Z. Molnar
Csaba P. Kovesdy
Kamyar Kalantar-Zadeh
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Diabetes Reports / Ausgabe 4/2012
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-012-0286-3

Weitere Artikel der Ausgabe 4/2012

Current Diabetes Reports 4/2012 Zur Ausgabe

Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Pathophysiology of Obesity-Related Renal Dysfunction Contributes to Diabetic Nephropathy

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Corticosteroid Use for Diabetic Macular Edema: Old Fad or New Trend?

Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Anti-Fibrosis Therapy and Diabetic Nephropathy

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Screening for Diabetic Retinopathy and Diabetic Macular Edema in the United Kingdom

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Small Fiber Neuropathy: Is Skin Biopsy the Holy Grail?

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.